ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the first quarter ended March 31, 2009. Total revenues for the first quarter 2009 increased 51 percent to $64.5 million from $42.7 million in 2008, primarily driven by increased sales of BioThrax® (Anthrax Vaccine Adsorbed), the company’s FDA licensed vaccine for the prevention of anthrax infection. Net income for the first quarter 2009 increased 58 percent to $11.1 million, or $0.37 per share, from $7.0 million, or $0.24 per share, for 2008.
